# PATENT COOPERATION TREATY

## **PCT**

REC'D	16 550
_	1 6 FEB 2006
WIPO	
	PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference ESTA-0423-WO	FOR FURTHER	ACTION	See Form PCT/IPEA/416		
International application No. International filing PCT/EP2005/001465 14.02.2005		te (day/month/year)	Priority date (day/month/year) 17.02.2004		
International Patent Classification (IPC) or national classification and IPC C07D231/06, A61K31/415, A61P3/06					
Applicant LABORATORIOS DR. ESTEVE S.	Α.				
Additionly under Afficie 33 and tra	nsmitted to the applic	ant according to Article	this International Preliminary Examining e 36.		
2. This REPORT consists of a total					
3. This report is also accompanied t					
a. $\square$ sent to the applicant and t	o the International Bu	reau) a total of sheets	s, as follows:		
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
□ sheets which superse beyond the disclosure Supplemental Box.	de earlier sheets, but in the international ap	which this Authority co oplication as filed, as in	onsiders contain an amendment that goes ndicated in item 4 of Box No. I and the		
b.   (sent to the International E sequence listing and/or table Box Relating to Sequence	nes relateu merem m	COMPUTER readable to	nber of electronic carrier(s)) , containing a rm only, as indicated in the Supplemental ve Instructions).		
4. This report contains indications re	lating to the following	items:			
☐ Box No. I Basis of the opin	nion				
☐ Box No. II Priority					
☐ Box No. III Non-establishm	ent of opinion with rec	ard to novelty invention	ve step and industrial applicability		
☐ Box No. IV Lack of unity of		and to horoky, myona	ve step and industrial applicability		
☐ Box No. V Reasoned state applicability; cita	ment under Article 35 Itions and explanation	(2) with regard to nove s supporting such stat	elty, inventive step or industrial tement		
Box No. VI Certain docume	nts cited				
$\square$ Box No. VII Certain defects in the international application					
⊠ Box No. VIII Certain observa	tions on the internatio	nal application			
Date of submission of the demand		Date of completion of	this report		
15.09.2005		15.02.2006			
Name and mailing address of the international preliminary examining authority:		Authorized Officer	const Palanten.		
European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016		De Jong, B Telephone No. +31 70	rivered .		

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2005/001465

_	Des No L F		
_	Box No. I B	Basis of the report	
1.	. With regard to the <b>language</b> , this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.		
	WHICH IS U	ort is based on translations from the original language into the following language , the language of a translation furnished for the purposes of:	
	□ publica	ational search (under Rules 12.3 and 23.1(b)) ation of the international application (under Rule 12.4) ational preliminary examination (under Rules 55.2 and/or 55.3)	
2.	2. With regard to the elements* of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):		
	Description, Pa	ages	
	1-55	as originally filed	
	Claims, Numbe	ers	
	1-86	as originally filed	
	Drawings, Sheets		
	1	as originally filed	
	☐ a sequend	ce listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing	
3.		dments have resulted in the cancellation of:	
	☐ the des	scription, pages ims, Nos.	
	☐ the dra	wings, sheets/figs quence listing <i>(specify)</i> :	
	☐ any tab	ple(s) related to sequence listing (specify):	
4.	Supplemental I	t has been established as if (some of) the amendments annexed to this report and listed below nade, since they have been considered to go beyond the disclosure as filed, as indicated in the Box (Rule 70.2(c)).	
	☐ the des ☐ the clai	scription, pages	
	☐ the dra	wings, sheets/figs	
	□ the seq □ any tab	luence listing <i>(specify)</i> : le(s) related to sequence listing <i>(specify)</i> :	
	* If item	4 applies, some or all of these sheets may be marked "superseded."	

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2005/001465

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-86

No: Claims

Inventive step (IS)

Yes: Claims

1-86

No: Claims

Industrial applicability (IA)

Yes: Claims

1-86

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

## Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2005/001465

Reference is made to the following documents:

D1: GB-A-1 209 326 (CARTER WALLACE) 21 October 1970

D2: EP-A-1 384 477 (LABORATORIOS DEL DR. ESTEVE) 28 January 2004

D3: WO 88/05046 A2 (E.I. DU PONT DE NEMOURS 14 July 1988

#### Re Item V.

#### **Novelty**

The compounds of the present application represent a novel selection from the compounds disclosed in D2. The compounds of D2 are useful against proliferative cell diseases.

The starting compound disclosed in example 17 of D3 is disclaimed in the present application.

Therefore the compounds according to the present application, there use and medicaments containing them are considered as novel.

## Inventive step

D1 discloses pyrrazole compounds which lower triglyceride levels in the blood plasma. In view of the various structural differences with the compounds of the present application, it was **not** obvious for the skilled person to arrive at the compounds of the present application starting from the teaching of D1.

#### Re Item VIII.

The vague and imprecise statement in the description on page 3 concerning **prodrugs**, implies that the subject-matter for which protection is sought may be different to that defined by the claims, thereby resulting in lack of clarity of the claims when used to interpret them.

Furthermore, the statement on page 46, lines 5-7 concerning the spirit of the invention is obviously unnecessary.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2005/001465

The document D1 (closest prior art) has not been identified in the description.